Patricia LoRusso, DO, discusses the benefit of genetic sequencing in soft tissue sarcomas.
Patricia M. LoRusso, DO
Advertisement
Articles by Patricia M. LoRusso, DO
Patricia M. LoRusso, DO, Professor of Medicine and Associate Director of Innovative Medicine, Yale Cancer Center, discusses taking a personalized medicine approach to treat melanoma patients whose tumors do not have BRAF alterations.
Patricia M. LoRusso, DO, Associate Director of Innovative Medicine, Yale Cancer Center, discusses the Dream Team Melanoma trial, which is investigating using personalized medicine to treat non-V600E melanoma subtypes.
Advertisement
Latest Updated Articles
Dr. LoRusso on Personalized Medicine for MelanomaPublished: April 15th 2015 | Updated:
Dr. Patricia LoRusso on Next-Generation Sequencing Benefit in Metastatic Melanoma TreatmentPublished: October 16th 2015 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5